budesonide

(redirected from Pulmicort Turbuhaler)
Also found in: Medical.
Related to Pulmicort Turbuhaler: Symbicort
Translations
budesonid

budesonide

n budesonida, budesónida (INN)
References in periodicals archive ?
His experience in successfully developing Rhinocort Aqua and Pulmicort Turbuhaler (topical budesonide, the active ingredient in Entocort) while at Astra will be instrumental to us as we advance orBec(R) to Phase 3 completion in GI GVHD.
Tokyo, Japan, Aug 3, 2006 - (JCN) - Astrazeneca announced on July 27 that it had received approval for its Pulmicort Turbuhaler, an inhaler for pediatric asthma infants from 6 months to under 5 years old, frrom the Japanese Ministry of Health, Labor and Welfare.
Assessment Of Adrenal Suppression From Two New Dry Powder Inhaler Formulations Of Budesonide Delivered By Clickhaler Compared With The Pulmicort Turbuhaler
Last week the company received an "approvable letter" from the Food and Drug Administration for its Pulmicort Turbuhaler, a medication used to treat asthma.
The FDA based its pregnancy rating label change for Pulmicort Turbuhaler on a review of data from three Swedish registries covering over 2,000 births from 1995 -1997 (Swedish Medical Birth Registry; Registry of Congenital Malformations and Child Cardiology Registry) that indicated no increased risk for congenital malformations from use of inhaled budesonide during early pregnancy -- the period when most major organ malformations can occur.
Pulmicort Turbuhaler is indicated for patients six years of age and older.
For copy of the full prescribing information for Pulmicort Turbuhaler or Pulmicort Respules, call 1-800-237-8898 or reference the website at www.
July 27 /PRNewswire/ -- A once-daily treatment regimen using the AstraZeneca LP inhaled corticosteroid, Pulmicort Turbuhaler (budesonide inhalation powder) in adult patients with stable, mild to moderate asthma showed significant improvement in asthma control, according to results in a newly published study in the July issue of the Journal of Allergy and Clinical Immunology (JACI).
This approval comes only eight months after the availability of Pulmicort Turbuhaler for use twice daily in adults and children in the U.
beta-blocker, and is at present introducing Pulmicort Turbuhaler, the